Showing results (491-500 of 2,410) with videos related to
Sort By:
Pageof 241
Journal of Medical Economics|May 6, 2024
Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United StatesSongkai Yan, Cheryl McDade, Kris Thiruvillakkat, et al.Journal of Medical Economics|April 30, 2024
Real-world total cost of care by line of therapy in relapsed/refractory diffuse large B-cell lymphomaJustin Gatwood, Anthony Masaquel, David Fox, et al.Journal of Medical Economics|May 31, 2024
Cost-effectiveness of the RefluxStop device for management of refractory gastroesophageal reflux disease in SwitzerlandSam Harper, Muralikrishnan Kartha, Stuart Mealing, et al.Journal of Medical Economics|January 23, 2026
Population-level assessment of healthcare cost-effectiveness from the payer's perspective in the Czech Republic: methodology and threshold setting using administrative dataMartina Fojtíková, Jindřich FialaJournal of Medical Economics|January 21, 2026
Calculating cost per event avoided using a composite number needed to treatJoshua Toliver, Julia Wang, Jigish Bhavsar, et al.Journal of Medical Economics|January 20, 2026
Cost-utility and budget impact analysis of dupilumab and oral Janus kinase (JAK) inhibitors for treating moderate-to-severe atopic dermatitis in TaiwanRachel Ai-Ting Yang, Valerie Tzu-Ning Liu, David Bin-Chia Wu, et al.Journal of Medical Economics|December 9, 2025
Association between elevations in alkaline phosphatase and healthcare utilization and costs among individuals with primary biliary cholangitis in the United StatesRobert G Gish, Michel H Mendler, Edward A Mena, et al.Journal of Medical Economics|November 21, 2025
Real-world disease burden and health care resource utilization for patients with Barth syndromeLindsay Marjoram, Yonglin Huang, Mary Kay Koenig, et al.Journal of Medical Economics|December 2, 2025
Cardio-renal-metabolic modeling in Asia-Pacific: projections of clinical and economic burden and empagliflozin's impact on burden reductionMichael Kim, Emma New, Andrew Lim, et al.Journal of Medical Economics|December 20, 2024
Health and economic impact of the 21-valent pneumococcal conjugate vaccine (V116) for adults in Japan: a delta price approachPeter P Mueller, Atsushi Tajima, Kelsie Cassell, et al.Pageof 241